Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Associate Professor of Medicine
Director, Vanderbilt AIDS Clinical Trials Center
Vanderbilt University
Nashville, TN

Topics of Professional Interest:
  • Complications of HIV
  • Impacts of genetic differences on HIV therapy response
  • HIV pathogenesis in the brain
  • Pharmacogenomics of HIV therapeutics
Current Professional Summary:

Dr Haas is the Director at Vanderbilt AIDS Clinical Trials Center. He is also an Associate Professor of Medicine, Division of Infectious Diseases, at Vanderbilt University School of Medicine. Dr Haas has broad experience in fundamental and clinical research, patient care, and teaching. He first acquired fundamental research skills studying covalent modifications of mRNA cap binding proteins. In 1994, he became Director of the HIV Inpatient Service for Vanderbilt University Hospital, with particular interest in mycobacterial infections, and authored numerous articles including the chapter on tuberculosis for Principles and Practices of Infectious Diseases. He leads the human genomics initiative of the AIDS Clinical Trials Group (ACTG). He has played a major role in studies addressing the relevance of variant drug metabolizing enzyme and transporter genes for efficacy and toxicity of nonnucleoside reverse transcriptase inhibitors, lymphocyte-P-glycoprotein activity during HIV infection, mitochondrial toxicity of nucleoside reverse transcriptase inhibitors, and gentic predictors of immune reconsitution. He has published more than 100 papers and book chapters, and is on the Editorial Review Board for Journal of Infectious Diseases.

Committees and Organizations:
  • Fellow, Infectious Diseases Society of America
  • Member, Infectious Diseases Society of Tennessee
  • Chair, AIDS Clinical Trials Group Pharmacology Committee
  • Member, AIDS Clinical Trials Group Executive Committee (2001)
Honors and Awards:
  • Editorial Advisory Board member, Journal of Infectious Diseases
  • Editorial Advisory Board member, Future HIV Therapy
Education:
  • Indiana University, BA, Chemistry, Summa Cum Laude (1975-1979)
  • Vanderbilt University School of Medicine, MD (1979-1983)
  • Vanderbilt University Medical Center, Medical Resident (1983-1986)
  • Nashville Veterans Affair Medical Center, Vandelbilt University Affiliated Hospital, Chief Medical Resident (1986-1987)
  • Vanderbilt University Medical Center, Fellow: Infectious Diseases (1987-1990)
Selected Publications:
  1. Haas DW, Wilkinson GR, Kuritzkes DR, et al. A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials. 2003;4:287-300.
  2. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
  3. Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS. 2005;19:1341-1349.
  4. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis. 2005;192:1931-1942.
  5. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006;42:401-407.
  6. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43:783-786.
  7. Ritchie MD, Haas DW, Motsinger AA, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis. 2006;43:779-782.
  8. Haas DW, Geraghty DE, Andersen JA, et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis. 2006;194:1098-1107.
  9. Motsinger AA, Ritchie MD, Shafer RW, et al. Multi-locus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group Study. Pharmacogenet Genomics. 2006;16:837-845.
  10. Kallianpur AR, Hulgan T, Canter JA, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS. 2006;20:1503-1513.